INDICATIONS FOR THE TREATMENT OF REPERFUSION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

Abstract

At the same time, it is especially important to assess the subsequent risk of developing cardiovascular complications in patients with myocardial infarction (MI) at the initial stage of the disease, since this contributes to a differentiated approach to therapy, improving the effectiveness of treatment and improving the quality of life of patients, which in general is of no small socio-economic importance.

A significant part of deaths is caused by acute myocardial infarction (AMI). In recent years, the point of view has become generally accepted that the most real factor in both the initiation and progression of atherosclerosis and the development of its acute clinical manifestations is inflammation, and the destabilization of the atherosclerotic plaque is determined by the high activity of the chronic inflammatory process in it. Of great interest is the study of specific markers of inflammation - cytokines, which may be prognostically more significant in determining the processes associated with the destabilization of the course of vascular atherosclerosis. There are a number of cytokines whose action is associated with the activation of inflammation in the atherosinflammatory plaque. Some of them, for example, tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), IL-6, have pro-inflammatory properties, the action of others, in particular IL-10, is associated with anti-inflammatory reactions.